Skip to content
Get Claritide

Amylin Alone At Twenty Percent

Eloralintide

Also known as LY3841136

Summary coverage

At a glance

What it is
Selective amylin agonist reaching −20% as monotherapy in Phase 2.
Evidence
Clinical trialsHow the tiers workLancet, 6 December 2025, Phase 2, NCT06230523, 263 participants, 48 weeks, once weekly subcutaneous: −9% at 1 mg, −12% at 3 mg, −18% at 6 mg, −20% at 9 mg, −20% on a 6→9 mg escalation and −16% on a 3→9 mg escalation, against −0.4% on placebo. Why this tier
Half-life
About 13 to 15 days
From Briere et al., Molecular Metabolism, 2025
Routes
Subcutaneous
Category
Metabolic
FDA
Investigational
As of 3 August 2026. What that means
WADA
We do not state a status

Putting Eloralintide on a schedule, with the vial it comes from and a log of each dose, happens in the app: Claritide for iPhone.

Evidence

Why this tier

Lancet, 6 December 2025, Phase 2, NCT06230523, 263 participants, 48 weeks, once weekly subcutaneous: −9% at 1 mg, −12% at 3 mg, −18% at 6 mg, −20% at 9 mg, −20% on a 6→9 mg escalation and −16% on a 3→9 mg escalation, against −0.4% on placebo. Nausea ran 11–64% across arms and fatigue reached 46% at 9 mg. Not approved.

Overview

What it is

Eloralintide is a selective long-acting amylin receptor agonist from Eli Lilly, given once weekly by subcutaneous injection. Its Phase 2, published in the Lancet in December 2025, reported up to 20% weight loss as monotherapy. An amylin agonist reaching that on its own is a category shift rather than an incremental result. It is not approved.

Mechanism

How it works

Amylin is co-secreted with insulin and signals meal termination, slows gastric emptying and suppresses post-meal glucagon. Eloralintide is a selective long-acting agonist at those receptors, without the GLP-1 arm that dominates the current class. That is what makes the Phase 2 result interesting: the weight loss is coming from a different pathway rather than from a larger dose of the same one.

Dosing

Commonly researched ranges

These are figures reported in published literature and practitioner protocols: a commonly researched range, not a recommendation. Claritide does not tell you what to take.
  • Phase 2 dose arms1–9 mg

    Once weekly for 48 weeks

    Four arms of 1, 3, 6 and 9 mg, plus 6→9 mg and 3→6→9 mg escalation arms, over 48 weeks. Those four figures are the whole ladder; a 5 mg or 7 mg dose has never been given. Weight loss ran 9.5% to 20.1% against 0.4% on placebo. Investigational: there is no approved regimen, and the Phase 3 doses are blinded.

Cycle guidance
Not established in available literature
Goals
Fat loss
Legal standing

Where this sits with the FDA

Dated, sourced, and separate from whether it works. Removal from a warning list is not permission to compound.
Investigationalas of 3 August 2026 · US

In Phase 2 development with no approval anywhere and no compounding pathway.

Primary source
Sport

WADA status

The 2026 Prohibited List entered force on 1 January 2026.
We do not state a status

Not named on the 2026 Prohibited List. We could not determine a classification and do not state one.

We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.

Reconstitution

Mixing recipes our sources document

Concentration (mg/mL) = vial mg ÷ diluent mL. On a U-100 barrel, 1 unit = 0.01 mL.

Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator

Expectations

Week by week

What our material describes people reporting. Individual responses vary widely.

Not established in available literature.

Tolerability

Side effects

Grouped by how often our sources report them. Percentages appear only where a published trial figure exists.

Common

  • NauseaReported at 11–64% across the dose arms: the spread is the story, and it climbs with dose.
  • Fatigue46% in trialsUp to 46% at the 9 mg dose.
Safety

Contraindications and interactions

Do not use if

Not established in available literature.

Interactions

Not established in available literature.

Absence from this list does NOT mean safety. It means lack of research.

Handling

Storage and cost

Storage
Our sources publish no reconstitution or storage protocol for eloralintide.
Cost
Not established in available literature
Deep dive

Eloralintide in full

Limited coverage

Eloralintide (LY3841136) is a selective long-acting amylin receptor agonist from Eli Lilly. Once weekly, subcutaneous.

The Phase 2

Published in the Lancet on 6 December 2025. NCT06230523, 263 participants, 48 weeks:

  • 1 mg: −9%
  • 3 mg: −12%
  • 6 mg: −18%
  • 9 mg: −20%
  • 6→9 mg escalation: −20%
  • 3→9 mg escalation: −16%
  • Placebo: −0.4%

Why it matters

Every drug at the top of the weight-loss class right now has a GLP-1 arm. Amylin has mostly been discussed as something to add to a GLP-1: cagrilintide exists commercially as half of CagriSema, not on its own.

An amylin agonist reaching −20% as monotherapy in Phase 2 is a different kind of result. It says the pathway can carry the effect by itself, which changes what combinations are worth building and what a person who tolerates GLP-1s badly might eventually be offered.

Tolerability is not free: nausea ran 11 to 64% across the dose arms and fatigue reached 46% at 9 mg. Phase 2 results also routinely shrink in Phase 3. It is cheap to carry this record now and useful to have it when the next readout lands.

References

Sources

  1. 1
    Lancet, 6 December 2025 · eloralintide Phase 2, NCT06230523, n=263
    PMID 41207310Source
  2. 2
    NCT06230523 · the arm labels carry the literal milligram doses: 1, 3, 6 and 9 mg weekly (dose review, 2026-08-17)
    Source

Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.